借助Bioquell技术一起对抗COVID-19的传播

Effective Against Emerging Pathogens

As an EPA registered sterilant and an Emerging Viral Pathogen Disinfectant, Bioquell has proven efficacy against dangerous pathogens. With over 50 peer reviewed studies and a history of eradicating emerging pathogens from surfaces, our proprietary 35% hydrogen peroxide vapor technology can make an impact against COVID-19.

Our experience against coronaviruses and dangerous pathogens started in 2003 against SARS, then 2014 combatting Ebola in the US and Europe, and 2017 to prevent MERS-CoV during the Hajj. Learn more about how our technology works to eliminate pathogens from every exposed surface here.

Download our COVID-19 case study Click here for a full list of Bioquell systems for Life Sciences Click here for a full list of Bioquell systems for healthcare

Maintain Operations with Bioquell

For many of our clients, particularly in the Life Sciences, shutting down simply is not an option. They are essential to the well-being of the nation, and, often, the world. Maintaining operations has become a priority during these tough times as critical areas are at great risk of exposure to the virus. Additionally, a new threat to business continuity has emerged, the impact of COVID-19 within the administrative and office spaces. Discover how Bioquell can help.

Watch the video Read About Business Continuity in IPI International Pharmaceutical Industry

In The News

Here are the latest stories about Bioquell related to COVID-19: